BACKGROUND/AIMS: ARO, an observational study of hemodialysis (HD) patients in Europe, aims to enhance our understanding of patient characteristics and practice patterns to improve patient outcome. METHODS:HD patients (n = 8,963) from 134 Fresenius Medical Care facilities treated between 2005 and 2006 were randomly selected from 9 European countries (Czech Republic, France, Hungary, Italy, Poland, Portugal, Spain, Slovak Republic and Slovenia) and Turkey. Information was captured on demographics, comorbidities, medications, laboratory and dialysis parameters, and outcome. RESULTS: Patients were followed for 1.4 ± 0.7 years. Wide variation by country was observed for age, sex and diabetes as a cause of chronic kidney disease. Cardiovascular disease was present in 73% of patients. Dialysis parameters were homogeneous across countries. Arteriovenous fistulas were frequently used (73%). More incident patients had hemoglobin <11 g/dl than prevalent patients (50 vs. 33%, respectively). Phosphatemia and intact parathyroid hormone were similar between incident and prevalent patients (4.7 ± 1.2 mg/dl and 190 vs. 213 ng/l, respectively). Medication use varied widely by country. In total, 5% of patients underwent renal transplantation. Overall death rate was 124/1,000 patient-years. CONCLUSION: ARO revealed differences in HD practice patterns and patient characteristics in the 10 participating countries. Future ARO studies will fill gaps in the knowledge about the care of European HD patients.
RCT Entities:
BACKGROUND/AIMS: ARO, an observational study of hemodialysis (HD) patients in Europe, aims to enhance our understanding of patient characteristics and practice patterns to improve patient outcome. METHODS:HDpatients (n = 8,963) from 134 Fresenius Medical Care facilities treated between 2005 and 2006 were randomly selected from 9 European countries (Czech Republic, France, Hungary, Italy, Poland, Portugal, Spain, Slovak Republic and Slovenia) and Turkey. Information was captured on demographics, comorbidities, medications, laboratory and dialysis parameters, and outcome. RESULTS:Patients were followed for 1.4 ± 0.7 years. Wide variation by country was observed for age, sex and diabetes as a cause of chronic kidney disease. Cardiovascular disease was present in 73% of patients. Dialysis parameters were homogeneous across countries. Arteriovenous fistulas were frequently used (73%). More incident patients had hemoglobin <11 g/dl than prevalent patients (50 vs. 33%, respectively). Phosphatemia and intact parathyroid hormone were similar between incident and prevalent patients (4.7 ± 1.2 mg/dl and 190 vs. 213 ng/l, respectively). Medication use varied widely by country. In total, 5% of patients underwent renal transplantation. Overall death rate was 124/1,000 patient-years. CONCLUSION:ARO revealed differences in HD practice patterns and patient characteristics in the 10 participating countries. Future ARO studies will fill gaps in the knowledge about the care of European HDpatients.
Authors: Isabella Cattinelli; Elena Bolzoni; Carlo Barbieri; Flavio Mari; José David Martin-Guerrero; Emilio Soria-Olivas; José Maria Martinez-Martinez; Juan Gomez-Sanchis; Claudia Amato; Andrea Stopper; Emanuele Gatti Journal: Health Care Manag Sci Date: 2011-11-15
Authors: Peter Stenvinkel; Iain A Gillespie; Jamie Tunks; Janet Addison; Florian Kronenberg; Tilman B Drueke; Daniele Marcelli; Guntram Schernthaner; Kai-Uwe Eckardt; Jürgen Floege; Marc Froissart; Stefan D Anker Journal: J Am Soc Nephrol Date: 2015-11-13 Impact factor: 10.121
Authors: Jürgen Floege; Iain A Gillespie; Florian Kronenberg; Stefan D Anker; Ioanna Gioni; Sharon Richards; Ronald L Pisoni; Bruce M Robinson; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt Journal: Kidney Int Date: 2015-02-04 Impact factor: 10.612
Authors: Kai-Uwe Eckardt; Iain A Gillespie; Florian Kronenberg; Sharon Richards; Peter Stenvinkel; Stefan D Anker; David C Wheeler; Angel L de Francisco; Daniele Marcelli; Marc Froissart; Jürgen Floege Journal: Kidney Int Date: 2015-04-29 Impact factor: 10.612
Authors: Nicholas Obermüller; Alexander R Rosenkranz; Hans-Walter Müller; Dennis Hidde; András Veres; Sabine Decker-Burgard; Isolde Weisz; Helmut Geiger Journal: Int J Mol Sci Date: 2017-09-28 Impact factor: 5.923
Authors: Iain A Gillespie; Iain C Macdougall; Sharon Richards; Vincent Jones; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt Journal: Pharmacoepidemiol Drug Saf Date: 2015-02-17 Impact factor: 2.890
Authors: Iain A Gillespie; Jürgen Floege; Ioanna Gioni; Tilman B Drüeke; Angel L de Francisco; Stefan D Anker; Yumi Kubo; David C Wheeler; Marc Froissart Journal: Pharmacoepidemiol Drug Saf Date: 2015-05-26 Impact factor: 2.890